|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007222,
umls-concept:C0008976,
umls-concept:C0011847,
umls-concept:C0011860,
umls-concept:C0020615,
umls-concept:C0030685,
umls-concept:C0030705,
umls-concept:C0035647,
umls-concept:C0042373,
umls-concept:C0205349,
umls-concept:C0220825,
umls-concept:C0332307,
umls-concept:C0391871,
umls-concept:C0392335,
umls-concept:C0441472,
umls-concept:C0678204,
umls-concept:C0680255,
umls-concept:C0725066,
umls-concept:C1283071,
umls-concept:C1530300,
umls-concept:C1963578,
umls-concept:C2587213
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2009-10-8
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
The relationship between cognitive function, cardiovascular disease and premature death is not well established in patients with type 2 diabetes. We assessed the effects of cognitive function in 11,140 patients with type 2 diabetes who participated in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Furthermore, we tested whether level of cognitive function altered the beneficial effects of the BP-lowering and glycaemic-control regimens in the trial.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1432-0428
|
|
pubmed:author |
pubmed-author:ADVANCE Collaborative Group,
pubmed-author:AndersonCC,
pubmed-author:ChalmersJJ,
pubmed-author:CooperMM,
pubmed-author:DufouilCC,
pubmed-author:GrobbeeD EDE,
pubmed-author:HackettMM,
pubmed-author:HamerRR,
pubmed-author:HellerS RSR,
pubmed-author:LishengLL,
pubmed-author:MacmahonSS,
pubmed-author:ManciaGG,
pubmed-author:NealBB,
pubmed-author:PatelAA,
pubmed-author:PillaiAA,
pubmed-author:PoulterNN,
pubmed-author:RaeA VAV,
pubmed-author:TraversAA,
pubmed-author:WoodwardMM,
pubmed-author:ZoungasSS,
pubmed-author:de GalanB EBE
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
52
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2328-36
|
|
pubmed:meshHeading |
pubmed-meshheading:19688336-Aged,
pubmed-meshheading:19688336-Antihypertensive Agents,
pubmed-meshheading:19688336-Cognition,
pubmed-meshheading:19688336-Cognition Disorders,
pubmed-meshheading:19688336-Diabetes Mellitus, Type 2,
pubmed-meshheading:19688336-Diabetic Angiopathies,
pubmed-meshheading:19688336-Drug Combinations,
pubmed-meshheading:19688336-Drug Therapy, Combination,
pubmed-meshheading:19688336-Educational Status,
pubmed-meshheading:19688336-Female,
pubmed-meshheading:19688336-Gliclazide,
pubmed-meshheading:19688336-Humans,
pubmed-meshheading:19688336-Hypoglycemia,
pubmed-meshheading:19688336-Hypoglycemic Agents,
pubmed-meshheading:19688336-Indapamide,
pubmed-meshheading:19688336-Male,
pubmed-meshheading:19688336-Mental Status Schedule,
pubmed-meshheading:19688336-Myocardial Infarction,
pubmed-meshheading:19688336-Perindopril,
pubmed-meshheading:19688336-Risk Factors,
pubmed-meshheading:19688336-Stroke
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
|
|
pubmed:affiliation |
The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050, Australia.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
